Maviret

Glecaprevir/pibrentasvir, the active ingredient in Maviret, is a NS3/4A protease inhibitor and NS5A inhibitor presented as a glecaprevir 300 mg / pibrentasvir 120 mg tablet for oral use. It treats chronic hepatitis C virus infection across genotypes 1‑6 in adults, including those with compensated cirrhosis, by blocking key steps in viral replication and assembly.

GNH USA supplies Maviret as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Maviret is indicated for the treatment of chronic hepatitis C virus infection, a viral liver disease. - Chronic hepatitis C (genotypes 1‑6): achieves sustained virologic response in the majority of adult patients. - Compensated cirrhosis due to hepatitis C: enables viral clearance while preserving liver function. - Treatment‑experienced adults: provides an effective pan‑genotypic option after prior therapy.

Maviret may cause adverse reactions; reported events vary in frequency.

Common Side Effects: - Headache - Fatigue - Nausea - Diarrhea - Abdominal pain - Itching (pruritus)

Serious or Rare Side Effects: - Elevated liver enzymes or hepatic decompensation - Severe allergic reactions such as rash or angioedema - Anemia - Jaundice or hepatic failure - Significant fatigue or weakness

When prescribing Maviret, consider the following precautions to ensure safe use. - Assess liver function: baseline hepatic enzymes and fibrosis stage should be evaluated. - Avoid in severe hepatic impairment: not recommended for Child‑Pugh B or C patients. - Monitor for drug‑drug interactions: review all concomitant medications. - Pregnancy and breastfeeding: safety not established; avoid unless benefit outweighs risk. - Renal function: monitor in severe renal impairment, although dose adjustment is not required. - Store at ambient temperature: keep below 25 °C, retain original packaging, and protect from moisture.

Maviret has a potential for drug‑drug interactions; review concomitant medicines before initiating therapy.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort): markedly reduce drug exposure. - Co‑administration with certain HCV NS5A inhibitors not approved together: may increase toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A inducers (e.g., efavirenz): may lower efficacy. - P‑glycoprotein inhibitors (e.g., itraconazole, ketoconazole): can increase plasma levels. - Acid‑reducing agents (e.g., omeprazole, ranitidine): may affect absorption. - Statins (simvastatin, lovastatin): increased risk of myopathy. - Certain antiretrovirals (atazanavir, darunavir): may require dose adjustment.